Cargando…
Novel Use of Bromelain and Acetylcysteine (BromAc®) for Pleural Involvement in Pseudomyxoma Peritonei
Pseudomyxoma peritonei (PMP) is a rare mucinous disease most commonly arising from the appendix. Pleural involvement arising from established PMP is seen in a small number of cases. Combined cytoreductive surgery and hyperthermic intrathoracic chemotherapy is the treatment of choice when managing in...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077436/ https://www.ncbi.nlm.nih.gov/pubmed/33976645 http://dx.doi.org/10.1159/000514273 |
_version_ | 1783684883675086848 |
---|---|
author | Lam, Anthony R. Bazzi, Khalil Valle, Sarah J. Morris, David L. |
author_facet | Lam, Anthony R. Bazzi, Khalil Valle, Sarah J. Morris, David L. |
author_sort | Lam, Anthony R. |
collection | PubMed |
description | Pseudomyxoma peritonei (PMP) is a rare mucinous disease most commonly arising from the appendix. Pleural involvement arising from established PMP is seen in a small number of cases. Combined cytoreductive surgery and hyperthermic intrathoracic chemotherapy is the treatment of choice when managing intra-thoracic PMP. In cases of recurrence, surgical intervention may be technically challenging and carry higher rates of complications, morbidity, and mortality. Bromelain and acetylcysteine (BromAc<sup>®</sup>) is a novel treatment modality that has demonstrated mucolytic properties. When injected directly into mucinous disease, it facilitates tumour dissolution and allows it to be aspirated. It has recently been tested in the treatment of inoperable peritoneal mucinous disease, with an acceptable safety profile and positive objective response. Here we describe the first two cases of BromAc<sup>®</sup> administered directly into pleural adenomucinosis, with striking differences in response between the two patients likely due to differences in tumour hardness. |
format | Online Article Text |
id | pubmed-8077436 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-80774362021-05-10 Novel Use of Bromelain and Acetylcysteine (BromAc®) for Pleural Involvement in Pseudomyxoma Peritonei Lam, Anthony R. Bazzi, Khalil Valle, Sarah J. Morris, David L. Case Rep Oncol Case Report Pseudomyxoma peritonei (PMP) is a rare mucinous disease most commonly arising from the appendix. Pleural involvement arising from established PMP is seen in a small number of cases. Combined cytoreductive surgery and hyperthermic intrathoracic chemotherapy is the treatment of choice when managing intra-thoracic PMP. In cases of recurrence, surgical intervention may be technically challenging and carry higher rates of complications, morbidity, and mortality. Bromelain and acetylcysteine (BromAc<sup>®</sup>) is a novel treatment modality that has demonstrated mucolytic properties. When injected directly into mucinous disease, it facilitates tumour dissolution and allows it to be aspirated. It has recently been tested in the treatment of inoperable peritoneal mucinous disease, with an acceptable safety profile and positive objective response. Here we describe the first two cases of BromAc<sup>®</sup> administered directly into pleural adenomucinosis, with striking differences in response between the two patients likely due to differences in tumour hardness. S. Karger AG 2021-03-31 /pmc/articles/PMC8077436/ /pubmed/33976645 http://dx.doi.org/10.1159/000514273 Text en Copyright © 2021 by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission. |
spellingShingle | Case Report Lam, Anthony R. Bazzi, Khalil Valle, Sarah J. Morris, David L. Novel Use of Bromelain and Acetylcysteine (BromAc®) for Pleural Involvement in Pseudomyxoma Peritonei |
title | Novel Use of Bromelain and Acetylcysteine (BromAc®) for Pleural Involvement in Pseudomyxoma Peritonei |
title_full | Novel Use of Bromelain and Acetylcysteine (BromAc®) for Pleural Involvement in Pseudomyxoma Peritonei |
title_fullStr | Novel Use of Bromelain and Acetylcysteine (BromAc®) for Pleural Involvement in Pseudomyxoma Peritonei |
title_full_unstemmed | Novel Use of Bromelain and Acetylcysteine (BromAc®) for Pleural Involvement in Pseudomyxoma Peritonei |
title_short | Novel Use of Bromelain and Acetylcysteine (BromAc®) for Pleural Involvement in Pseudomyxoma Peritonei |
title_sort | novel use of bromelain and acetylcysteine (bromac®) for pleural involvement in pseudomyxoma peritonei |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077436/ https://www.ncbi.nlm.nih.gov/pubmed/33976645 http://dx.doi.org/10.1159/000514273 |
work_keys_str_mv | AT lamanthonyr noveluseofbromelainandacetylcysteinebromacforpleuralinvolvementinpseudomyxomaperitonei AT bazzikhalil noveluseofbromelainandacetylcysteinebromacforpleuralinvolvementinpseudomyxomaperitonei AT vallesarahj noveluseofbromelainandacetylcysteinebromacforpleuralinvolvementinpseudomyxomaperitonei AT morrisdavidl noveluseofbromelainandacetylcysteinebromacforpleuralinvolvementinpseudomyxomaperitonei |